News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
296,291 Results
Type
Article (14818)
Company Profile (258)
Press Release (281215)
Section
Business (91072)
Career Advice (154)
Deals (16102)
Drug Delivery (28)
Drug Development (53317)
Employer Resources (31)
FDA (6748)
Job Trends (5510)
News (164049)
Policy (12293)
Tag
Academia (945)
Africa (192)
Allergies (31)
Alliances (25784)
Alzheimer's disease (719)
Antibody-drug conjugate (ADC) (30)
Approvals (6719)
Arizona (40)
Artificial intelligence (27)
Asia (29248)
Australia (4208)
Bankruptcy (102)
Best Places to Work (4548)
Biotechnology (216)
C2C Services and Suppliers (16106)
California (1105)
Canada (490)
Cancer (216)
Career advice (135)
CAR-T (32)
Cell therapy (82)
China (83)
Clinical research (41560)
Collaboration (73)
Colorado (33)
Compensation (27)
Connecticut (35)
COVID-19 (1051)
Cystic fibrosis (58)
Data (125)
Diabetes (32)
Diagnostics (1575)
Earnings (32673)
Employer resources (29)
Europe (42846)
Events (49395)
Executive appointments (75)
FDA (6849)
Florida (109)
Funding (76)
Gene therapy (71)
GLP-1 (272)
Government (1170)
Healthcare (7032)
Hotbed/Location (200395)
Illinois (66)
Indiana (42)
Infectious disease (1059)
Inflammatory bowel disease (77)
IPO (7943)
Job creations (1037)
Job search strategy (131)
Kansas (55)
Layoffs (178)
Legal (2111)
Liver cancer (31)
Lung cancer (44)
Maryland (176)
Massachusetts (922)
Medical device (3426)
Medtech (3427)
Mergers & acquisitions (8146)
Metabolic disorders (118)
Michigan (34)
Minnesota (77)
Neuroscience (807)
New Jersey (301)
New York (354)
NextGen Class of 2024 (2095)
Non-profit (875)
North Carolina (326)
Northern California (495)
Obesity (70)
Ohio (58)
Opinion (85)
Parkinson's disease (26)
Patents (34)
Peanut (27)
Pennsylvania (255)
People (27153)
Pharmaceutical (41)
Phase I (14270)
Phase II (19133)
Phase III (12584)
Pipeline (71)
Postmarket research (981)
Preclinical (5979)
Press Release (32)
Rare diseases (94)
Real estate (1856)
Regulatory (9446)
Research institute (970)
South America (270)
Southern California (453)
Startups (2166)
Texas (94)
United States (4336)
Vaccines (122)
Washington State (143)
Weight loss (53)
Date
Last 7 days (366)
Last 30 days (1202)
Last 365 days (22844)
2024 (15361)
2023 (23971)
2022 (30256)
2021 (31145)
2020 (26604)
2019 (18343)
2018 (13442)
2017 (15641)
2016 (13742)
2015 (16812)
2014 (12453)
2013 (9312)
2012 (9526)
2011 (9709)
2010 (9315)
296,291 Results for "carrick therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts and Appoints David Sutherland, CPA, as Vice President of Finance and Controller
Carrick Therapeutics Inc. today announced the relocation of its corporate headquarters from Dublin, Ireland to Boston, Massachusetts.
June 5, 2024
·
2 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Carrick Therapeutics today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib (CT7001).
February 14, 2024
·
4 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer
Carrick Therapeutics today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating the novel combination of Carrick’s samuraciclib (CT7001).
October 18, 2023
·
6 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer
Carrick Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating the combination of samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, and fulvestrant, an intramuscular injected selective estrogen receptor degrader (SERD), in women with HR+, HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor.
December 15, 2023
·
3 min read
Business
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Carrick Therapeutics today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE).
July 6, 2023
·
5 min read
Genetown
Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.
September 7, 2023
·
2 min read
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
Genetown
Carrick Therapeutics Closes Series C Financing
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing.
December 1, 2022
·
2 min read
Press Releases
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
August 16, 2024
·
5 min read
Press Releases
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
July 22, 2024
·
5 min read
1 of 29,630
Next